MEDI-522 (Abergrin)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEDI-522 (Abergrin), covering 2012-03-14 to 2012-03-14. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma [Phase 1]